Novo Nordisk (NVO) boosted its guidance for the second time in two months as demand soars for its diabetes treatments, Ozempic and Wegovy. 澳洲幸运5官方开奖结果体彩网:Am♈erican depositary receipts (ADRs) of Novo Nordisk rose close to 2% to an all-time high 🐻on Friday following the news. 

The Danish drugmaker now predicts full-year sales will increase 32% to 38%, up from its 澳洲幸运5官方开奖结果体彩网:previous forecast of a gain of 27% to 33%. It anticipates 澳洲幸运5官方开奖结果体彩网:operating profit growth of 40% to 46% versus its earlier estimate of 31% to 37%.

Novo Nordisk noted that t𓃲he change was primarily reflected in higher expectations for Ozempic volumes in the U.S., and 𒈔gross-to-net sales adjustments for Ozemic and Wegovy in the U.S.

For the third quarter and first n🌺ine months o꧑f the year, Novo Nordisk expects revenue growth of 38% and 33%, respectively. Operating profit expansion over the same periods are projected at 47% and 37%, respectively. Those results are scheduled to be released Nov. 2.

The success of Ozempic and Wegovy in helping patien༺ts lose weight has led to a boom in demand. In August, the company reported sales of its treatments skyrocketed 158% in the first six months of the year. 

Ozempic and Wegovy are being tested for other uses as well. Earlier this week, Novo Nordisk reported it had 澳洲幸运5官方开奖结果体彩网:halted a trial of Ozempic to treat chronic kidney disease early because preliminary results showed signs of success. Two months ago, it 澳洲幸运5官方开奖结果体彩网:released results of a study that indicated Wegovy was succesꦓsful in reducing major adverse cardiovascular events in patients with cardi✅ovascular disease.